Share Twitter LinkedIn Facebook Email HER2-Low: Anastrozole TRIO-US B-12 TALENT SABCS 2022 Aditya Bardia, MD of Mass General discusses theGS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer Advertisement
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read
Fertility Preservation: Interrupting endocrine therapy to attempt pregnancy in Breast Cancer Breast 2 Mins Read